All News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Real-time Estimate Cboe BZX Other stock markets 10:41:09 29/04/2024 pm IST			5-day change	1st Jan Change
12.94 ^USD	+2.45%		+8.58%	-13.97%

24/04	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
10/04	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	24/04	BU
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	24/04	CI
NovoCure : Corporate responsibility report	22/04	PU
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	10/04	MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	08/04	AQ
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	05/04	MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	05/04	BU
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	03/04	MT
Novocure to Report First Quarter 2024 Financial Results	01/04	BU
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	28/03	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	28/03	AQ
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients	27/03	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	27/03	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03	MT
Sector Update: Health Care	27/03	MT
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell	27/03	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	27/03	MT
Transcript : NovoCure Limited - Special Call	27/03
Novocure's lung cancer therapy succeeds in late-stage trial	27/03	RE
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	27/03	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

All News

Filters